Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients With Rheumatoid Arthritis Interstitial Lung Disease (TRAIL1)

NCT02808871 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT02808871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02808871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients With Rheumatoid Arthritis Interstitial Lung Disease (TRAIL1)
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 2
Overall status
Completed
Start date
April 7, 2017
Completion date
April 7, 2021
Enrollment
123 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis interstitial lung disease